Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Tewari, Krishnansu S, Sill, Michael W, Penson, Richard T, Huang, Helen, Ramondetta, Lois M, Landrum, Lisa M, Oaknin, Ana, Reid, Thomas J, Leitao, Mario M, Michael, Helen E, DiSaia, Philip J, Copeland,Language:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(17)31607-0
Date:
July, 2017
File:
PDF, 580 KB
english, 2017